Erratum to: Targ Oncol
DOI 10.1007/s11523-012-0225-x
Some errors occurred in the publication of this article. It should read:
Conflict of interest Dr. Simona Grozinsky-Glasberg serves as an invited speaker for Novartis and IPSEN.
Financial disclosures for Professor Marianne Pavel: 1. Grant - Institution - Novartis 2. Consulting fee or honorarium - Novartis, Pfizer, IPSEN 3. Support for travel to meetings for the study or other purposes - Novartis 4. Fees for participation in review activities such as data monitoring boards, statistical analysis, end point committees, and the like -none 5. Payment for writing or reviewing the manuscript - None 6. Provision of writing assistance, medicines, equipment, or administrative support- None.
In Table 1:
Correct references:
US-52 [26]
RADIANT-2 [27]
RAMSETE [29]
Correct values for RADIANT-2 Median PFS: 16.4 vs 11.3 (placebo) instead of 16.3 vs 11.
In the following sentence, the reference has been changed to 25 rather than 22:
Thirdly, it remains unclear in which treatment line everolimus should be used. So far, data from RADIANT-3 trial [25] did not show any differences in efficacy depending on previous use of chemotherapy, compared to the use of everolimus in therapy-naive patients.
The below reference has been corrected:
27. Pavel ME, Hainsworth JD, Baudin E et al. (2011) Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 378:2005–2012
Author information
Authors and Affiliations
Corresponding author
Additional information
The online version of the original article can be found at http://dx.doi.org/10.1007/s11523-012-0225-x.
Rights and permissions
About this article
Cite this article
Grozinsky-Glasberg, S., Pavel, M. Erratum to: Inhibition of mTOR in carcinoid tumors. Targ Oncol 7, 197 (2012). https://doi.org/10.1007/s11523-012-0232-y
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11523-012-0232-y